Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies: (Details) (USD $)	12 Months Ended
	Feb. 28, 2013 item	Feb. 29, 2012
Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies:
Percentage of outstanding stock owned by the President and Chairman of the Board	80.90%
Number of antineoplaston drugs that have received FDA approval	0
Economic Dependency
Working capital deficit	$ 87,000
Accumulated deficit	108,099,879	101,601,073
Losses incurred	6,498,806	7,157,662
Estimated percentage of Dr. Burzynski's patients admitted and treated as part of clinical trial programs	10.00%
Income Taxes
Uncertain tax positions	$ 0	$ 0
Loss Per Common Share
Warrants and stock options excluded from calculation of diluted loss per share	1,600,000	600,000
Fair Value of Financial Instruments
Number of financial instruments held for trading purposes	0
Minimum
Property and Equipment
Estimated useful lives	5 years
Maximum
Property and Equipment
Estimated useful lives	10 years